The study of Grant et al. [55] showed that a depression and anxiety score generally tends to improve in GLP-1 analog exenatide-treated T2DM patients and it could be used as an adjunctive therapy for depression in diabetes. The gene discussed is GLP1R; the disease is depressive symptom measurement.